tirzepatide landmark trial for masld maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled Tirzepatide for Heart Failure with

Some clinical studies back up these claims

California Proposition 65 Notice : California law requires the following notice: WARNING - Some products may expose you to chemicals known to the State of California to cause cancer, birth defects, or other reproductive harm

Convenience: Tirzepatide is administered once a week by injection, which may be more convenient for some people than other weight loss medications that require more frequent dosing

Side Effects and Safety Profile Oral and injectable GLP-1 medications share similar side effects, though the frequency and severity differ due to absorption differences

They are reported here for research orientation, not as a treatment protocol